Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.

Molecular & cellular proteomics : MCP - 1 May 2015

Brooke Greg N, Gamble Simon C, Hough Michael A, Begum Shajna, Dart D Alwyn, Odontiadis Michael, Powell Sue M, Fioretti Flavia M, Bryan Rosie A, Waxman Jonathan, Wait Robin, Bevan Charlotte L

Abstract excerpt

Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen receptor, which repress androgen-stimulated growth. These include the selective androgen receptor modulators cyproterone acetate and hydroxyflutamide and the complete antagonist bicalutamide. Their activity is partly dictated by the presence of androgen receptor mutations, which are commonly detected in patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Sequence Annotation

Share to Neoplasm Proteins

Share to Nitriles

Share to Prostate

Share to Proteome

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 25693800
DOI: 10.1074/mcp.M113.036764
PMCID: PMC4424393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.PMID 25693800Read ↗

Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.Semantic proximity Read ↗

A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.Semantic proximity Read ↗

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.Semantic proximity Read ↗

Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.Semantic proximity Read ↗

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell LinesSemantic proximity Read ↗

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate CancerSemantic proximity Read ↗

Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic InterventionSemantic proximity Read ↗

5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read ↗

The Early Effects of Rapid Androgen Deprivation on Human Prostate CancerSemantic proximity Read ↗

Overcoming mutation-based resistance to antiandrogens with rational drug design.Semantic proximity Read ↗

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.Semantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.